Education
About Us
Working with TipRanks
Follow Us
Mayne Pharma Group (AU:MYX)
ASX:MYX
MYX Stock Chart & Stats
AU$6.01
-AU$0.13(-2.74%)
At close: 4:00 PM EST
AU$6.01
-AU$0.13(-2.74%)
Day’s Range― - ―
52-Week RangeAU$2.27 - AU$7.31
Previous CloseN/A
Volume149.18K
Average Volume (3M)593.75K
Market Cap
AU$188.49M
Enterprise ValueAU$165.76M
Total Cash (Recent Filing)AU$67.35M
Total Debt (Recent Filing)AU$44.62M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding81,245,830
10 Day Avg. Volume776,050
30 Day Avg. Volume593,750
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.10Price Target Upside1.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginA ~3.9ppt gross margin improvement indicates a structurally higher-quality revenue mix. Sustained margin expansion supports long-term profitability resilience, gives flexibility to fund marketing and R&D, and cushions the business against pricing pressure in generics markets.
Positive Operating Cash Flow & Strong Cash BalanceConsistent positive operating cash flow and a substantial cash buffer provide runway for strategic initiatives. This durable cash position enables targeted investment, deleveraging or buybacks, and reduces refinancing risk while management executes growth and margin improvements.
Dermatology Margin-led TurnaroundShift toward a branded dermatology mix has materially boosted margins and direct contribution. Branded products generally yield more stable, higher-margin cash flows than pure generics, supporting a durable structural move to higher profitability and better operating leverage over time.
Bears Say
Weak Profitability / Negative ROEPersistent negative net margins and a -25% ROE show the company is not converting revenue into equity returns. Even with gross margin strength, structural operating losses limit reinvestment capacity, hinder capital allocation options, and require sustained operational fixes to restore profitability.
Poor Cash Conversion And FCF DeclineSeverely negative FCF growth and low cash conversion mean earnings do not reliably turn into liquid resources. This structural weakness constrains capex, M&A and shareholder returns, increasing dependency on existing cash or external funding until conversion improves sustainably.
Ongoing Litigation And Large One-off ChargesMaterial noncash earn‑out adjustments and active litigation create profit volatility and potential significant cash outflows. Ongoing legal exposure and transaction costs can persist for many quarters, complicating forecasting, diverting management focus and limiting capital deployment flexibility.
Mayne Pharma Group News
MYX FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest share price was AU$2.27 and its highest was AU$7.31 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is AU$188.49M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 156 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Feb 22, 2026. The company reported -AU$0.15 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.15.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Undervalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of AU$0.544 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -AU$0.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.783%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in AU:MYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.10 (1.50% Upside)
AU$6.10 (1.50% Upside)
Blogger Sentiment
Bullish
AU:MYX Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$401.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-23.02%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MYX Company Deck
MYX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.View all AU:MYX earnings summariesMYX Stock 12 Month Forecast
Average Price Target
AU$6.10
▲(1.50% Upside)
Technical Analysis
Cogstate Ltd
―
Immutep Ltd
―
Dimerix Limited
―
Clarity Pharmaceuticals Ltd.
―
Cyclopharm Limited
―
Options Prices
Currently, No data available
---